Optimizing the clinical pharmacology of tuberculosis medications.

Optimizing the clinical pharmacology of tuberculosis medications.

Item
http://www.wikidata.org/entity/Q38542159
Insights into the pharmacokinetic properties of antitubercular drugs.Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysisMight isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis.Developing and Using Therapeutics for Emerging Infections.Reply to Alffenaar et al.Applying optimization algorithms to tuberculosis antibiotic treatment regimens.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Targeting protein biotinylation enhances tuberculosis chemotherapy.Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"
P2860

Optimizing the clinical pharmacology of tuberculosis medications.

Item
http://www.wikidata.org/entity/Q38542159
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Optimizing the clinical pharmacology of tuberculosis medications.
@en
type
label
Optimizing the clinical pharmacology of tuberculosis medications.
@en
prefLabel
Optimizing the clinical pharmacology of tuberculosis medications.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Optimizing the clinical pharmacology of tuberculosis medications
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698